AstraZeneca and Alteogen agree on ALT-B4 platform tech

AstraZeneca has entered an exclusive licence agreement with Alteogen involving the latter’s ALT-B4 platform technology.

Leave a Reply

Your email address will not be published. Required fields are marked *